InvestorsHub Logo
Followers 32
Posts 2821
Boards Moderated 3
Alias Born 10/24/2015

Re: None

Monday, 05/02/2022 4:59:46 PM

Monday, May 02, 2022 4:59:46 PM

Post# of 29
1115: Epigenetic Reprogramming (Epi-R™) Yields T-Cell Receptor Products with Improved Stemness, Metabolic Fitness, and Functional Activity in the Presence of Persistent Antigen Exposure

661: Preclinical Development of LYL797, a ROR1-Targeted CAR T-Cell Therapy Enhanced with Genetic and Epigenetic Reprogramming for Solid Tumors
Day Range:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent LYEL News